Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review

Journal of the American College of Cardiology

Volumn 72, Issue 15, 2018, Pages 1845-1855

  Zelniker, Thomas A ^a,b   Braunwald, Eugene ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

diabetes; heart failure; renal function; SGLT2 inhibitor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMPAGLIFLOZIN; ERTUGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN; ANTIDIABETIC AGENT;

ALBUMINURIA; ARTERIAL PRESSURE; BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DEHYDRATION; DIABETIC NEPHROPATHY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; ESTIMATED GLOMERULAR FILTRATION RATE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEMATOCRIT; HOSPITALIZATION; HUMAN; HYDROPHILICITY; HYPOGLYCEMIA; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MEMBRANE PERMEABILITY; MICROCIRCULATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; SODIUM TRANSPORT; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; CARDIOVASCULAR SYSTEM; DRUG EFFECT; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHARMACOLOGY; TREATMENT OUTCOME;

CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85054426104     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.06.040     Document Type: Review

References (81)

1. Summary of revisions: standards of medical care in diabetes-2018. Diabetes Care 41 Suppl 1 (2018), S4–S6.
2. McMurray, J.J., Gerstein, H.C., Holman, R.R., Pfeffer, M.A., Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
3. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
4. Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
5. U.S. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed November 24, 2017.
6. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
7. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
8. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
9. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
10. Crane, R.K., Intestinal absorption of sugars. Physiol Rev 40 (1960), 789–825.
11. Wright, E.M., Turk, E., The sodium/glucose cotransport family SLC5. Pflugers Arch 447 (2004), 510–518.
12. Hummel, C.S., Lu, C., Loo, D.D., Hirayama, B.A., Voss, A.A., Wright, E.M., Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300 (2011), C14–C21.
13. Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
14. Petersen, C., Analyse des Phloridzins. Annalen der Pharmacie, 15, 1835, 178.
15. Meng, W., Ellsworth, B.A., Nirschl, A.A., et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51 (2008), 1145–1149.
16. Miao, Z., Nucci, G., Amin, N., et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos 41 (2013), 445–456.
17. Scheen, A.J., Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 53 (2014), 213–225.
18. Kasichayanula, S., Liu, X., Lacreta, F., Griffen, S.C., Boulton, D.W., Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 53 (2014), 17–27.
19. Devineni, D., Polidori, D., Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin Pharmacokinet 54 (2015), 1027–1041.
20. Zambrowicz, B., Freiman, J., Brown, P.M., et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92 (2012), 158–169.
21. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
22. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
23. Fitchett, D., Butler, J., van de Borne, P., et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 39 (2018), 363–370.
24. Mahaffey, K.W., Neal, B., Perkovic, V., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 137 (2018), 323–334.
25. Radholm, K., Figtree, G., Perkovic, V., et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation, 2018 Mar 11 [E-pub ahead of print].
26. Sonesson, C., Johansson, P.A., Johnsson, E., Gause-Nilsson, I., Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol, 15, 2016, 37.
27. Wu, J.H., Foote, C., Blomster, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 411–419.
28. Birkeland, K.I., Jorgensen, M.E., Carstensen, B., et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5 (2017), 709–717.
29. Kosiborod, M., Lam, C.S.P., Kohsaka, S., et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol 71 (2018), 2628–2639.
30. Udell, J.A., Yuan, Z., Rush, T., Sicignano, N.M., Galitz, M., Rosenthal, N., Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 137 (2018), 1450–1459.
31. Suissa, S., Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?. Diabetes Care 41 (2018), 6–10.
32. Wiviott, S.D., Raz, I., Bonaca, M.P., et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 trial. Am Heart J 200 (2018), 83–89.
33. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
34. Voors, A.A., van der Horst, I.C., Diabetes: a driver for heart failure. Heart 97 (2011), 774–780.
35. Boudina, S., Abel, E.D., Diabetic cardiomyopathy revisited. Circulation 115 (2007), 3213–3223.
36. Shimizu, I., Yoshida, Y., Katsuno, T., et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab 15 (2012), 51–64.
37. Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
38. Baker, W.L., Smyth, L.R., Riche, D.M., Bourret, E.M., Chamberlin, K.W., White, W.B., Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8 (2014), 262–275.e9.
39. Sha, S., Polidori, D., Heise, T., et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 16 (2014), 1087–1095.
40. Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K.D., Ferrannini, E., energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1730–1735.
41. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
42. Inzucchi, S.E., Zinman, B., Fitchett, D., et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), 356–363.
43. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86 (2014), 1057–1058.
44. Yoshimoto, T., Furuki, T., Kobori, H., et al. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med 65 (2017), 1057–1061.
45. Shin, S.J., Chung, S., Kim, S.J., et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One, 11, 2016, e0165703.
46. + and vasodilation. Diabetologia 61 (2018), 722–726.
47. Pogwizd, S.M., Sipido, K.R., Verdonck, F., Bers, D.M., Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res 57 (2003), 887–896.
48. Cingolani, H.E., Ennis, I.L., Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation 115 (2007), 1090–1100.
49. Ferrannini, E., Baldi, S., Frascerra, S., et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65 (2016), 1190–1195.
50. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
51. Sato, T., Aizawa, Y., Yuasa, S., et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol, 17, 2018, 6.
52. Packer, M., Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation 137 (2018), 1614–1631.
53. Umanath, K., Lewis, J.B., Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis 71 (2018), 884–895.
54. Schwartz, M.M., Lewis, E.J., Leonard-Martin, T., Lewis, J.B., Batlle, D., Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 13 (1998), 2547–2552.
55. Ronco, C., Haapio, M., House, A.A., Anavekar, N., Bellomo, R., Cardiorenal syndrome. J Am Coll Cardiol 52 (2008), 1527–1539.
56. Bock, J.S., Gottlieb, S.S., Cardiorenal syndrome: new perspectives. Circulation 121 (2010), 2592–2600.
57. Sharma, K., Ziyadeh, F.N., Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes 44 (1995), 1139–1146.
58. Braam, B., Joles, J.A., Danishwar, A.H., Gaillard, C.A., Cardiorenal syndrome–current understanding and future perspectives. Nat Rev Nephrol 10 (2014), 48–55.
59. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
60. Burke, M., Pabbidi, M.R., Farley, J., Roman, R.J., Molecular mechanisms of renal blood flow autoregulation. Curr Vasc Pharmacol 12 (2014), 845–858.
61. Peti-Peterdi, J., Harris, R.C., Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol 21 (2010), 1093–1096.
62. Ortola, F.V., Ballermann, B.J., Anderson, S., Mendez, R.E., Brenner, B.M., Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 80 (1987), 670–674.
63. Cherney, D.Z.I., Zinman, B., Inzucchi, S.E., et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
64. Stanton, R.C., Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?. Circulation 129 (2014), 542–544.
65. Santer, R., Calado, J., Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5 (2010), 133–141.
66. Garg, S.K., Henry, R.R., Banks, P., et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377 (2017), 2337–2348.
67. Inzucchi, S.E., Iliev, H., Pfarr, E., Zinman, B., Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), e4–e5.
68. Verma, S., Mazer, C.D., Al-Omran, M., et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137 (2018), 405–407.
69. European Medicines Agency. SGLT2 Inhibitors: Information on Potential Risk of Toe Amputation to Be Included in Prescribing Information. 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_Canagliflozin_20/European_Commission_final_decision/WC500227101.pdf. Accessed June 4, 2018.
70. Watts, N.B., Bilezikian, J.P., Usiskin, K., et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101 (2016), 157–166.
71. Turk, E., Zabel, B., Mundlos, S., Dyer, J., Wright, E.M., Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 350 (1991), 354–356.
72. U.S. Food and Drug Administration. FDA Warns That SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood. 2015. Available at: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf. Accessed June 4, 2018.
73. Taylor, S.I., Blau, J.E., Rother, K.I., SGLT2 Inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100 (2015), 2849–2852.
74. Bonner, C., Kerr-Conte, J., Gmyr, V., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21 (2015), 512–517.
75. Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., Parikh, S., Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 103 (2014), 373–381.
76. Kohler, S., Lee, J., George, J.T., Inzucchi, S.E., Zinman, B., Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia 60 (2017), 2534–2535.
77. Wanner, C., Lachin, J.M., Inzucchi, S.E., et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137 (2018), 119–129.
78. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 41 Suppl 1 (2018), S73–S85.
79. Piepoli, M.F., Hoes, A.W., Agewall, S., et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
80. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
81. U.S. Food and Drug Administration. FDA Approves Jardiance to Reduce Cardiovascular Death in Adults With Type 2 Diabetes. 2016. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed June 4, 2018.